Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Survival: 7.7 months
Toxicity Grade: 3
Treatments: Chemotherapy
Drugs: Temodar
Country: United States
City/State/Province: New York, New York
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 1/2002

Twenty-eight patients had recurrent glioblastoma multiforme and seven patients had various types of recurrent anaplastic glioma. All patients had resection at diagnosis and all but one patient had prior radiotherapy. Twenty-seven patients had received prior chemotherapy.

Treatment: Treatment in this study consisted of the drug temozolomide (temodar).

Toxicity: Grade 3 toxicities occurred in 8 patients (thrombocytopenia, neutropenia and lymphopenia). Other grade 1 and grade 2 toxicities included: hemoglobin, constipation, fatigue, nausea, vomiting, and changes in liver enzymes (i.e. ALP, ALT, AST).

Results: Glioblastoma multiforme patients had a median survival of 7.7 months (measured from the day of study entry).

Support: This study was supported in part by an unrestricted grant from Integrated Therapeutics, Inc. Integrated Therapeutics, Inc. is a subsidiary of Schering-Plough Corporation. Schering-Plough Corporation markets temozolomide.

E-mail to a Friend More Information